Research Article

Calcium Carbonate versus Sevelamer Hydrochloride as Phosphate Binders after Long-Term Disease Progression in 5/6 Nephrectomized Rats

Suvi Törmänen,¹ Arttu Eräranta,¹ Asko Riutta,¹ Peeter Kööbi,^{1,2}
Teemu Honkanen,¹ Emmanouil Karavalakis,¹ Onni Niemelä,³ Heikki Tokola,⁴
Heikki Ruskoaho,⁴ Jukka Mustonen,^{1,5} and Ilkka Pörsti^{1,5}

¹ School of Medicine, University of Tampere, 33014 Tampere, Finland

² Department of Ophthalmology, Tampere University Hospital, P.O. Box 2000, 33521 Tampere, Finland

³ Department of Clinical Chemistry, Etelä-Pohjanmaa Central Hospital Laboratory, 60220 Seinäjoki, Finland

⁴ Department of Pharmacology and Toxicology, Biocenter Oulu, University of Oulu, P.O. Box 5000, 99014 Oulu, Finland

⁵ Department of Internal Medicine, Tampere University Hospital, P.O. Box 2000, 33521 Tampere, Finland

Correspondence should be addressed to Ilkka Pörsti; ilkka.porsti@uta.fi

Received 17 May 2014; Revised 2 July 2014; Accepted 5 August 2014; Published 24 August 2014

Academic Editor: Carlos G. Musso

Copyright © 2014 Suvi Törmänen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Our aim was to compare the effects of calcium carbonate and sevelamer-HCl treatments on calcium-phosphate metabolism and renal function in 5/6 nephrectomized (NX) rats so that long-term disease progression preceded the treatment. After 15-week progression, calcium carbonate (3.0%), sevelamer-HCl (3.0%), or control diets (0.3% calcium) were given for 9 weeks. Subtotal nephrectomy reduced creatinine clearance (−40%), plasma calcidiol (−25%), and calcitriol (−70%) and increased phosphate (+37%), parathyroid hormone (PTH) (11-fold), and fibroblast growth factor-23 (FGF-23) (4-fold). In NX rats, calcium carbonate diet increased plasma (+20%) and urinary calcium (6-fold), reduced plasma phosphate (−50%) and calcidiol (−30%), decreased creatinine clearance (−35%) and FGF 23 (−85%), and suppressed PTH without influencing blood pH. In NX rats, sevelamer-HCl increased urinary calcium (4-fold) and decreased creatinine clearance (−45%), PTH (−75%), blood pH (by 0.20 units), plasma calcidiol (−40%), and calcitriol (−65%). Plasma phosphate and FGF-23 were unchanged. In conclusion, when initiated after long-term progression of experimental renal insufficiency, calcium carbonate diet reduced plasma phosphate and FGF-23 while sevelamer-HCl did not. The former induced hypercalcemia, the latter induced acidosis, while both treatments reduced vitamin D metabolites and deteriorated renal function. Thus, delayed initiation influences the effects of these phosphate binders in remnant kidney rats.

1. Introduction

Cardiovascular disease is a major cause of mortality in chronic renal insufficiency (CRI) with a 20-fold increase in the risk of cardiovascular death compared with normal population [1]. Hyperphosphatemia and secondary hyperparathyroidism (SHPT) [2] significantly contribute to the cardiovascular pathology and mineral-bone disorders in CRI. In order to halt these changes, oral phosphate binders such as calcium carbonate and sevelamer are widely used.

High intake of calcium carbonate may predispose to vascular calcifications in CRI, especially if the phosphate

levels remain inappropriately high [2]. Consequently, treatment with sevelamer, a calcium- and aluminium-free and nonabsorbable polyallylamine anion exchange resin, may result in less vascular calcifications and reduced mortality in dialysis patients. However, according to recent Cochrane review, the superiority of sevelamer over calcium carbonate remains unclear [3].

In experimental animal models, increased calcium intake has resulted in beneficial effects on blood pressure (BP), endothelial function, sodium-potassium balance, inflammation and thrombosis, plasma cholesterol levels, and insulin

FIGURE 1: The flow chart of the study. Surgery (5/6 nephrectomy, NX; Sham-operation, Sham) was performed at entry, followed by 15-week disease progression period. The animals were then allocated to control (0.3% calcium; Sham, NX), 3% calcium carbonate (Ca-Sham and Ca-NX), or 3% sevelamer-HCl diet (Seve-Sham and Seve-NX) for 9 weeks. The values in parentheses indicate the number of animals/group at each phase of the experiment.

sensitivity [4]. We have recently reported in three separate studies that phosphate binding using calcium carbonate suppressed angiotensin-converting enzyme (ACE) expression in the kidney [5, 6], enhanced vasorelaxation of mesenteric arteries via endogenous NO, and suppressed elevation of aortic ACE and nitrated proteins in experimental CRI [7].

Sevelamer has a clinically proven positive impact on SHPT, and it has also been reported to improve plasma lipid profile and endothelial function in renal patients [3, 8]. However, when bound to hydrochloride, it has aggravated metabolic acidosis in uremic patients due to increased acid load [9], and it was subsequently replaced by sevelamer carbonate [10, 11]. The previous studies using sevelamer-HCl might have had both negative and positive bias due to metabolic acidosis, which has been reported to decrease serum calcitriol [12–14], negatively influence bone mineral deposition [15], reduce cardiovascular calcifications [16], and negatively influence overall survival [9]. Of note, information on pH was not included in the majority of previous experimental CRI studies using sevelamer-HCl [17–29]. There is also evidence that sevelamer can impair the absorption of vitamin D and other liposoluble molecules from the gut [30–32].

In most of the experimental CRI studies, various treatments have been started very shortly after the induction of renal damage, but this is seldom possible in clinical practice. In particular, complications like calcium carbonate-induced hypercalcemia and sevelamer-HCl-induced acidosis might constitute more severe problems in well-established CRI after a prolonged period of compromised mineral and acid-base balance. Our aim was to examine the influences of long-term 3.0% calcium carbonate and 3.0% sevelamer-HCl treatments on calcium-phosphate metabolism and kidney function, and also on cardiac load and survival, in the surgical 5/6 nephrectomy rat model of CRI so that an extended 15-week disease progression period preceded the treatments.

2. Methods

2.1. Animals and Experimental Design. Ninety-five male Sprague-Dawley rats were subjected to surgical 5/6 nephrectomy (NX, $n = 51$) or Sham operation ($n = 44$) at 8 weeks of age under ketamine/diazepam anesthesia (75 and 2.5 mg/kg, resp.). The NX surgery comprised removal of the upper and lower poles of the left kidney followed by contralateral nephrectomy. In the Sham group both kidneys were decapsulated [5]. All rats were housed 3–4 per cage in an animal laboratory with free access to water and chow containing 0.9% calcium and 0.8% phosphate (Lactamin R34, AnalyCen, Lindköping, Sweden). Average daily chow intake was approximately 20 grams per rat, monitored in metabolic cages.

After 15 weeks of disease progression, NX and Sham rats were divided into three subgroups with equal systolic BPs, body weights, and urine outputs (Figure 1). BP was measured using tail-cuff (Model 129 BP Meter; IITC Inc., Woodland Hills, CA, USA). NX groups were matched according to plasma creatinine concentrations. Then for 9 weeks, Sham ($n = 14$) and NX ($n = 20$) groups continued on 0.3% calcium, Ca-Sham ($n = 15$) and Ca-NX ($n = 16$) rats on 3% calcium carbonate, and Seve-Sham ($n = 15$) and Seve-NX ($n = 15$) rats on 3% sevelamer-HCl. The doses of phosphate binders (estimated at 1.3 g/kg) were chosen on the basis of previous reports, none of which had reported major adverse effects with 3.0% calcium carbonate or 3.0% sevelamer-HCl ingestion [17–29, 33, 34]. Sevelamer carbonate was not available at the time this study was conducted. As 0.9% calcium content in control chow is rather high, and lower dietary calcium content has been used in several publications [19, 33, 34], the calcium content in the present control chow was reduced to 0.3% similarly to our previous reports in experimental CRI [5, 6].

During the final week, 24-hour water consumption was measured and urine output was collected in metabolic

cages. Then BPs were measured, and rats were weighed and anesthetized (urethane 1.3 g/kg, intraperitoneally). Blood and tissue samples were collected and stored at -70°C . Due to mortality, the final numbers for analyses in the uremic NX, Ca-NX, and Seve-NX groups were 12, 11, and 10, respectively (Figure 1). In each uremic group there was one rat that survived through the 24-week experiment but expired before BP measurements and sample collections and was only included in the survival analyses.

The study design was approved by Tampere University Animal Experimentation Committee and Provincial Government of Western Finland, Department of Social Affairs and Health, Finland. The investigation conforms to the *Guide for the Care and Use of Laboratory Animals* published by the US National Institutes of Health (NIH Publication Number 85-23, revised 1996).

2.2. Hormonal and Chemical Analyses. Sodium, potassium, creatinine, phosphate, and calcium concentrations were measured by standard clinical chemical methods (Cobas Integra 800 Clinical Chemical Analyzer, Roche Diagnostics, Basel, Switzerland). Hemoglobin was determined photometrically (Technicon H*2, Technicon Instruments Corporation, Tarrytown, NY, USA), plasma pH was determined using an ion selective electrode (634 pH Analyzer, Ciba Corning Diagnostics, Sudbury, UK), and rat intact parathyroid hormone (PTH) levels were determined by immunoradiometric assay (Immutopics Inc., San Clemente, CA, USA). Plasma $1,25(\text{OH})_2\text{D}$ and $25(\text{OH})\text{D}$ were determined using commercial kits (IDS Ltd, Boldon, UK) and plasma fibroblast growth factor-23 (FGF-23) was determined using ELISA kit previously applied for analyses in rats (Kainos Inc., Tokyo, Japan) [35]. Ventricular atrial natriuretic peptide (ANP) mRNA was isolated and the radioimmunoassay was carried out as described previously [36].

2.2.1. Calcification Analysis in the Aorta. Altogether 20 cross-sections of the thoracic and 20 cross-sections of the abdominal aorta from each animal were cut, and every 5th of these sections were stained with the von Kossa method and processed for light microscopy. An expert blinded to the treatments quantified the calcifications.

2.2.2. Data Presentation and Analysis of Results. Statistical analysis for normally distributed variables was carried out using one-way analysis of variance (ANOVA) supported by Tukey's HSD test in the post hoc analyses (SPSS 17.0, SPSS Inc., Chicago, IL, USA). If the distribution of a variable was skewed, the Kruskal-Wallis test was applied and the post hoc analyses were performed with the Mann-Whitney U test. Results were expressed as mean $\pm$ SEM. Survival was analyzed using the Kaplan-Meier curves and the log-rank test. $P < 0.05$ denoted significance.

3. Results

3.1. Animal Data, Electrolytes, Renal Function, and Blood pH. Figure 2 shows the survival rates in nephrectomized rats, which were 65%, 75%, and 73% for NX, Ca-NX, and Seve-NX,

FIGURE 2: Survival rates in Sham-operated and 5/6 nephrectomized rats presented with Kaplan-Meier curves. Sham groups, all Sham-operated groups; NX, 5/6 nephrectomized rats; Ca, 3% calcium carbonate diet; Seve, 3% sevelamer-HCl diet; $n = 9-15$; * $P < 0.05$ versus Sham, # $P < 0.05$ versus Ca-Sham, † $P < 0.05$ versus NX, and ‡ $P < 0.05$ versus Ca-NX. P values for NX groups and for NX versus Sham groups are given.

respectively ($P = 0.782$). Table 1 shows the characteristics and laboratory findings in the study groups. There were no significant differences in body weights between the groups during the experiment ($P > 0.114$). The weights of the removed kidney masses did not differ between the three NX groups ($P = 0.924$). Before the treatments at week 15, no differences were observed in BP ($P = 0.739$). At week 24, BP was elevated in all nephrectomized rats ($P < 0.001$), while Ca-NX rats had lower BP than other uremic groups ($P < 0.047$). Heart weight/body weight ratios were increased in the NX and Seve-NX groups ($P \leq 0.004$) (Table 1). Increased left ventricular ANP gene expression was detected in all NX groups ($P < 0.001$), showing the cardiac load in this model (Figure 3(a)).

Plasma creatinine was equally elevated in all NX groups before the diets ($P = 0.849$) (Table 1). At week 24, creatinine was 1.7-fold higher in the NX than the Sham group ($P < 0.001$). Most likely due to the loss of the animals with the worst renal function, creatinine was not further elevated in the NX group during the final 9-week follow-up. Both Seve-NX ($P < 0.009$) and Ca-NX ($P = 0.016$) groups had higher creatinine concentrations at week 24 than untreated NX rats (Table 1). The 24-hour urine output was increased in all NX groups ($P \leq 0.005$) and was especially high in Seve-NX rats ($P < 0.001$) (Figure 3(b)). Creatinine clearance was reduced by ~40% in untreated NX rats ($P < 0.001$) and was further reduced in the CaNX (-35% , $P = 0.01$) and Seve-NX groups

TABLE 1: Characteristics and laboratory findings in the study groups.

	Sham	Ca-Sham	Seve-Sham	NX	Ca-NX	Seve-NX
Weight of kidney tissue removed in the 5/6 nephrectomy (g/kg)				6.3 ± 0.1	6.2 ± 0.1	6.2 ± 0.2
Body weight (g)						
Week 15	454 ± 11	452 ± 8	452 ± 7			
Week 24	495 ± 13	474 ± 8	504 ± 12	438 ± 7	447 ± 11	442 ± 16
Systolic blood pressure (mmHg)				476 ± 11	467 ± 16	459 ± 17
Week 15	125 ± 10	123 ± 9	118 ± 5	127 ± 6	133 ± 7	132 ± 5
Week 24	135 ± 4	136 ± 4	144 ± 7	169 ± 4*	151 ± 5*†	167 ± 9*
Creatinine (μmol/L)						
Week 15	n.d.	n.d.	n.d.	88.2 ± 5.3	87.3 ± 7.1	88.6 ± 5.5
Week 24	49.6 ± 2.6	52.5 ± 1.9	53.2 ± 2.5	84.5 ± 7.6*	128.8 ± 25.7*†	161.7 ± 33.2*†
Sampling at close of the study (week 24)						
pH	7.40 ± 0.05	7.43 ± 0.03	7.22 ± 0.07*#	7.41 ± 0.03	7.34 ± 0.05	7.21 ± 0.04*†
Sodium (mmol/L)	136.0 ± 0.5	135.7 ± 0.3	136.1 ± 0.5	136.7 ± 0.5	135.4 ± 0.6	138.2 ± 1.2
Potassium (mmol/L)	3.92 ± 0.09	3.79 ± 0.21	3.90 ± 0.07	4.49 ± 0.15*	4.88 ± 0.24*	5.12 ± 0.23*†
Hemoglobin (g/L)	177.3 ± 2.1	175.0 ± 2.2	182.0 ± 1.3	158.3 ± 4.6*	157.3 ± 3.9*	143.9 ± 8.8*†‡
Heart wt/body wt (g/kg)	3.48 ± 0.07	3.40 ± 0.06	3.92 ± 0.44	4.53 ± 0.48*	4.26 ± 0.23	5.45 ± 0.51**
Ca-Pi product (mmol ² /L ²)	3.03 ± 0.14	2.05 ± 0.11*	3.22 ± 0.17#	4.10 ± 0.49*	2.49 ± 0.26*†	5.24 ± 0.53*‡
Urine sampling at close of the study (week 24)						
Protein (mg/24 h)	70.8 ± 8.0	74.2 ± 10.0	111.2 ± 26.8	242.3 ± 31.6*	260.5 ± 46.4*	285.2 ± 38.8*

Mean ± SEM; n = 10–20 (see Figure 1); n.d. = not determined.

*P < 0.05 versus Sham, †P < 0.05 versus NX, ‡P < 0.05 Ca-NX versus Seve-NX, and #P < 0.05 Ca-Sham versus Seve-Sham.

FIGURE 3: Left ventricular ANP mRNA (a), urine volume (b), creatinine clearance (c), and 24-hour urinary calcium excretion at the close of the study. Sham, sham-operated rats; NX, 5/6 nephrectomized rats; Ca, 3% calcium carbonate diet; Seve, 3% sevelamer-HCl diet; $n = 9-15$; * $P < 0.05$ versus Sham, # $P < 0.05$ versus Ca-Sham, † $P < 0.05$ versus NX, and ‡ $P < 0.05$ versus Ca-NX.

(-45% , $P = 0.01$) when compared with untreated NX rats (Figure 3(c)).

A blood pH reduction of approximately 0.2 units was observed in both Sham and NX rats on sevelamer-HCl ($P < 0.012$) (Table 1). Plasma potassium was elevated in all NX groups ($P < 0.019$), especially in Seve-NX rats ($P < 0.001$). There were no significant differences in plasma sodium concentrations between the groups ($P = 0.108$). Hemoglobin was decreased in all NX groups ($P \leq 0.004$) and was lowest in Seve-NX rats ($P < 0.001$). Urinary protein excretion was equally increased in all NX groups ($P \geq 0.920$) and was ~ 3.5 -fold higher in NX than in Sham rats ($P \leq 0.003$) (Table 1).

3.2. Calcium-Phosphate Metabolism. Urinary calcium excretion did not differ between the NX and the Sham groups ($P = 0.830$) (Figure 3(d)) but was increased 10-fold in Ca-Sham rats ($P < 0.001$) and 6-fold in Ca-NX rats ($P < 0.001$).

An increase in urinary calcium excretion was documented in uremic rats which were on sevelamer-HCl ($P = 0.008$) (Figure 3(d)). Plasma calcium was highest in Ca-NX rats ($P \leq 0.004$) but was also increased in Ca-Sham ($P < 0.001$) and Seve-NX rats ($P = 0.023$) (Figure 4(a)), so that calcium levels did not differ in the two latter groups ($P = 0.964$). Plasma phosphate was increased in NX ($P = 0.01$) and Seve-NX rats ($P = 0.001$) and reduced in Ca-Sham ($P < 0.001$) and Ca-NX rats ($P = 0.002$) (Figure 4(b)). Plasma Ca-Pi product was elevated in the NX ($P = 0.011$) and Seve-NX groups ($P = 0.001$) but was reduced in both calcium-supplemented groups ($P \leq 0.047$) (Table 1).

Plasma calcidiol was reduced by approximately 25% in untreated NX rats ($P = 0.019$) and was further decreased in the Ca-NX ($P = 0.032$) and Seve-NX groups ($P = 0.002$) (by $\sim 30\%$ and $\sim 40\%$ versus the untreated NX group, resp.). Sevelamer-HCl reduced calcidiol concentration also in

FIGURE 4: Plasma total calcium (a), phosphate (b), 25OH-D (c), 1,25(OH)₂D (d), FGF-23 (e), and PTH (f) at the close of the study. Groups as in Figure 3; **P* < 0.05 versus Sham, #*P* < 0.05 versus Ca-Sham, †*P* < 0.05 versus NX, and ‡*P* < 0.05 versus Ca-NX.

Sham-rats by 25% ($P = 0.009$) (Figure 4(c)). Calcitriol was low in all uremic rats ($P < 0.001$), while both treatments ($P \leq 0.001$), especially sevelamer-HCl, decreased calcitriol even in Sham rats (Figure 4(d)). FGF-23 levels were suppressed in Ca-NX rats ($P < 0.001$), whereas in NX and Seve-NX rats FGF-23 remained high ($P \leq 0.043$) (Figure 4(e)). PTH was increased 11-fold in the NX group ($P = 0.001$) and was totally suppressed in both Ca-Sham and Ca-NX rats ($P < 0.001$). PTH was also reduced by 75% in the Seve-NX group ($P = 0.036$), probably due to the elevated plasma calcium in these animals (Figure 4(f)).

Even though altogether 8 aortic cross-sections were analyzed from each rat, calcifications in the aortic samples were scarce. In all uremic groups there were two rats with calcifications in the thoracic aorta, while one rat in the Ca-NX and one in the Seve-NX group also had calcifications in the abdominal aorta.

4. Discussion

In the present study, we examined the effects of calcium carbonate and sevelamer-HCl in established experimental CRI with prolonged disease progression period preceding the treatments. Unexpectedly, the undesirable side effects of calcium carbonate and sevelamer-HCl overshadowed their positive effects, and the treatments showed no survival benefits. Calcium carbonate suppressed PTH and FGF-23 but caused hypercalcemia especially in Ca-NX rats with impaired renal excretion capacity. Sevelamer-HCl induced acidosis in both Sham-operated and uremic rats, and consequently no decreases in plasma phosphate or FGF-23 were seen. Sevelamer-HCl also increased plasma calcium and urinary calcium excretion and decreased PTH in NX rats. Both treatments reduced vitamin D metabolites and impaired kidney function. Neither calcium carbonate nor sevelamer-HCl influenced aortic calcifications or mortality. The aortic calcifications were scarce, as the NX model is quite resistant to soft-tissue calcification in the absence of excess calcitriol or phosphate loading [6, 37]. In previous studies, sevelamer-HCl treatment did not induce renoprotective effects in experimental CRI if irreversible kidney damage had already taken place [21] but was clearly beneficial if initiated right after the kidney insult [24].

The phosphate binding and FGF-23-reducing ability of sevelamer-HCl [3, 20] seemed low in our study, although estimated sevelamer-HCl intake was approximately 1300 mg/kg/day in each rat (thus clearly exceeding the maximum dose of about 140 mg/kg/day in an average 70 kg human). The acidosis of Seve-Sham and Seve-NX rats indicates that they received hydrogen ions in excess in the diet. Acidosis and consequent impairment of kidney function with reduced phosphate excreting capacity were the likely explanation for the high phosphate levels in Seve-NX rats. Acidosis can deteriorate kidney function, whereas bicarbonate treatment can delay the progression of CRI [38]. When the present results were adjusted for the differences in creatinine, plasma phosphate was numerically lower in the Seve-NX than NX group (1.61 versus 1.75 mmol/L,

resp.). Creatinine clearance did not differ between Ca-NX and Seve-NX rats, but the phosphate and the FGF-23 levels were lower in Ca-NX rats, showing that calcium carbonate functioned as a phosphate binder in this model.

A reason for the elevated phosphate in Seve-NX rats may have been the calcium- and phosphate-releasing effect of metabolic acidosis on bone [9, 15]. Increased urinary calcium excretion in Seve-Sham and Seve-NX rats strongly indicates increased calcium efflux from bone in the acidic milieu [9]. As sevelamer-HCl is not absorbed and only binds phosphate in the gut [9], it is not able to influence phosphate levels resulting from increased internal release. The acidosis-induced release of bone minerals was the likely cause for increased plasma calcium and the subsequent significant decrease in plasma PTH in Seve-NX rats, since extracellular fluid calcium concentration is the primary regulator of PTH release from the parathyroid glands [39]. In the Ca-NX rats, significant dietary hypercalcemia was the most likely cause for the deteriorated kidney function.

Although plasma calcitriol and calcidiol levels are typically reduced in CRI [40], we observed a further decline of calcidiol in Ca-NX and Seve-NX rats, which may have partially resulted from accelerated CRI in these animals. The reasons for low plasma calcidiol in CRI are multiple, including urinary loss of vitamin D binding protein and vitamin D metabolites, reduced gastrointestinal absorption, and decreased 25-hydroxylation in the liver [41]. Importantly, decrease in calcidiol and calcitriol in the Seve-Sham group corresponded to the reduction observed in untreated NX rats. Changes in calcium, phosphate, PTH, creatinine clearance [14], FGF-23 [35], and urine protein excretion [42] would all potentially influence plasma vitamin D metabolite concentrations. However, these variables did not differ between Sham and Seve-Sham rats. Sevelamer-HCl also binds bile acids in the gut [31] and interferes with the absorption of fat-soluble vitamins D, E, and K [30, 32]. This may explain the decreased plasma calcidiol in Seve-Sham rats. In addition, reduced calcitriol in Seve-Sham rats may also have resulted from acidosis, which has been implicated in downregulation of α -hydroxylation and upregulation of 24-hydroxylation [14]. In calcium carbonate-treated rats, potential mechanisms for the reduced vitamin D metabolites were hypercalcemia and subsequent suppression of PTH and impaired kidney function of the Ca-NX group.

The present model of CRI was associated with increased heart weight and left ventricular ANP mRNA expression. Such changes can be explained by higher BP, volume load, anemia, increased FGF-23, and vitamin D deficiency in the NX groups [43–45]. Highest heart weights were observed in Seve-NX rats, probably due to accelerated CRI, increased volume load, and aggravated anemia [43]. Furthermore, lowest calcitriol was seen in the Seve-NX rats and their FGF-23 was equally high as in the untreated NX rats. Both of these mechanisms have the potential to aggravate LVH [44, 45].

Acidosis may have influenced the results obtained in previous sevelamer-HCl studies. Only two [33, 34] of the fifteen experimental sevelamer-HCl studies reported blood pH [17–29, 33, 34], and these studies applied the ligation model of 5/6 nephrectomy with a disease progression period

of only one week. Rats received 3.0% sevelamer-HCl or 3.0% calcium carbonate for 12 weeks in the former study and for 24 weeks in the latter study. High mortality (about 80%) in the latter study was observed in each uremic group. In the surviving 20%, sevelamer-HCl had beneficial effects on phosphate, PTH, and kidney function. Sevelamer-HCl also increased calciuresis when compared with uremic controls [33, 34]. Of note, the ligation 5/6 nephrectomy model results in increased plasma renin activity [46, 47], while the surgical model used here is characterized by low plasma renin and reduced aldosterone [5, 48]. Low plasma aldosterone level decreases hydrogen ion excretion in the kidneys [49], and this probably exposed the present rats to acidosis. Reduced pH in Seve-Sham rats indicates that excess hydrochloride could cause acidosis even in healthy rats. In those previous experimental studies with sevelamer-HCl that did not report blood pH, increased plasma calcium concentration was attributed to reduced phosphate levels [17–21, 29]. Some studies also found increased calciuresis [17, 22, 25], which was thought to result from reduced PTH [22, 25]. A dose-dependent decrease in plasma calcitriol after sevelamer-HCl treatment was observed in two previous studies [17, 25], one of which also showed a clear reduction in plasma calcidiol [17].

In conclusion, late-onset treatment with calcium carbonate or sevelamer-HCl after 15 weeks of disease progression in the 5/6 nephrectomy rat model of CRI showed no survival benefits, and both treatments deteriorated kidney function and reduced plasma calcidiol and calcitriol. In both Sham-operated and remnant kidney rats, sevelamer-HCl treatment induced acidosis, while calcium carbonate treatment induced hypercalcemia. Finally, oral calcium carbonate, but not sevelamer-HCl, effectively suppressed plasma phosphate and FGF-23. Altogether, the present doses of phosphate binders, albeit based on previous publications [5, 6, 48], seemed too high for this model. The present findings also indicate that the results from previous studies using sevelamer-HCl in experimental CRI should be interpreted with caution due to the possible bias resulting from acidosis-induced changes in calcium-phosphate metabolism.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

Acknowledgments

This study was supported by the Medical Research Fund of Tampere University Hospital, Academy of Finland, Finnish Kidney Foundation, Finnish Foundation for Cardiovascular Research, Paavo Nurmi Foundation, Pirkanmaa Regional Fund of Finnish Cultural Foundation, The Emil Aaltonen Foundation, and Sigrid Juselius Foundation. Sevelamer hydrochloride was generously donated by Genzyme Corporation (Cambridge, MA, USA).

References

- [1] R. N. Foley, P. S. Parfrey, and M. J. Sarnak, "Epidemiology of cardiovascular disease in chronic renal disease," *Journal of the American Society of Nephrology*, vol. 9, no. 12, pp. S16–S23, 1998.
- [2] G. M. Chertow, P. Raggi, S. Chasan-Taber, J. Bommer, H. Holzer, and S. K. Burke, "Determinants of progressive vascular calcification in haemodialysis patients," *Nephrology Dialysis Transplantation*, vol. 19, no. 6, pp. 1489–1496, 2004.
- [3] S. D. Navaneethan, S. C. Palmer, M. Vecchio, J. C. Craig, G. J. Elder, and G. F. Strippoli, "Phosphate binders for preventing and treating bone disease in chronic kidney disease patients," *Cochrane Database of Systematic Reviews*, vol. 2, Article ID CD006023, 2011.
- [4] L. Wang, J. E. Manson, and H. D. Sesso, "Calcium intake and risk of cardiovascular disease: a review of prospective studies and randomized clinical trials," *American Journal of Cardiovascular Drugs*, vol. 12, no. 2, pp. 105–116, 2012.
- [5] A. Eräranta, A. Riutta, M. Fan et al., "Dietary phosphate binding and loading alter kidney angiotensin-converting enzyme mRNA and protein content in 5/6 nephrectomized rats," *American Journal of Nephrology*, vol. 35, no. 5, pp. 401–408, 2012.
- [6] I. Pörssti, M. Fan, P. Kööbi et al., "High calcium diet down-regulates kidney angiotensin-converting enzyme in experimental renal failure," *Kidney International*, vol. 66, no. 6, pp. 2155–2166, 2004.
- [7] A. Eräranta, S. Törmänen, P. Kööbi et al., "Phosphate binding reduces aortic Angiotensin-converting enzyme and enhances nitric oxide bioactivity in experimental renal insufficiency," *American Journal of Nephrology*, vol. 39, pp. 400–408, 2014.
- [8] K. Caglar, M. I. Yilmaz, M. Saglam et al., "Short-term treatment with sevelamer increases serum fetuin-a concentration and improves endothelial dysfunction in chronic kidney disease stage 4 patients," *Clinical Journal of the American Society of Nephrology*, vol. 3, no. 1, pp. 61–68, 2008.
- [9] B. Brezina, W. Y. Qunibi, and C. R. Nolan, "Acid loading during treatment with sevelamer hydrochloride: mechanisms and clinical implications," *Kidney International*, vol. 66, no. 90, pp. S39–S45, 2004.
- [10] S. Mathew, R. J. Lund, F. Strebeck, K. S. Tustison, T. Geurs, and K. A. Hruska, "Reversal of the adynamic bone disorder and decreased vascular calcification in chronic kidney disease by sevelamer carbonate therapy," *Journal of the American Society of Nephrology*, vol. 18, no. 1, pp. 122–130, 2007.
- [11] M. Tokumoto, M. Mizobuchi, J. L. Finch, H. Nakamura, D. R. Martin, and E. Slatopolsky, "Blockage of the renin-angiotensin system attenuates mortality but not vascular calcification in uremic rats: sevelamer carbonate prevents vascular calcification," *The American Journal of Nephrology*, vol. 29, no. 6, pp. 582–591, 2009.
- [12] H. Kawashima, J. A. Kraut, and K. Kurokawa, "Metabolic acidosis suppresses 25-hydroxyvitamin D3-1 α -hydroxylase in the rat kidney. Distinct site and mechanism of action," *The Journal of Clinical Investigation*, vol. 70, no. 1, pp. 135–140, 1982.
- [13] S. W. Lee, J. Russell, and L. V. Avioli, "25 Hydroxycholecalciferol to 1,25 dihydroxycholecalciferol: conversion impaired by systemic metabolic acidosis," *Science*, vol. 195, no. 4282, pp. 994–996, 1977.
- [14] A. J. Brown, A. Dusso, and E. Slatopolsky, "Vitamin D," *American Journal of Physiology*, vol. 277, no. 2, pp. F157–F175, 1999.

- [15] D. A. Bushinsky, "The contribution of acidosis to renal osteodystrophy," *Kidney International*, vol. 47, no. 6, pp. 1816–1832, 1995.
- [16] F. J. Mendoza, I. Lopez, A. Montes De Oca, J. Perez, M. Rodriguez, and E. Aguilera-Tejero, "Metabolic acidosis inhibits soft tissue calcification in uremic rats," *Kidney International*, vol. 73, no. 4, pp. 407–414, 2008.
- [17] G. J. Behets, M. Gritters, G. Dams, M. E. De Broe, and P. C. D'Haese, "Effects of efficient phosphate binding on bone in chronic renal failure rats," *Renal Failure*, vol. 27, no. 4, pp. 475–484, 2005.
- [18] K. Katsumata, K. Kusano, M. Hirata et al., "Sevelamer hydrochloride prevents ectopic calcification and renal osteodystrophy in chronic renal failure rats," *Kidney International*, vol. 64, no. 2, pp. 441–450, 2003.
- [19] M. Kuwahara, S. Inoshita, Y. Terada, and S. Sasaki, "Effect of sevelamer hydrochloride on bone in experimental uremic rats," *Therapeutic Apheresis and Dialysis*, vol. 13, no. 1, pp. 42–48, 2009.
- [20] N. Nagano, S. Miyata, M. Abe et al., "Effect of manipulating serum phosphorus with phosphate binder on circulating PTH and FGF23 in renal failure rats," *Kidney International*, vol. 69, no. 3, pp. 531–537, 2006.
- [21] N. Nagano, S. Miyata, M. Abe, S. Wakita, N. Kobayashi, and M. Wada, "Sevelamer hydrochloride reverses parathyroid gland enlargement via regression of cell hypertrophy but not apoptosis in rats with chronic renal insufficiency," *Nephrology Dialysis Transplantation*, vol. 21, no. 3, pp. 634–643, 2006.
- [22] N. Nagano, S. Miyata, S. Obana et al., "Renal mineral handling in normal rats treated with sevelamer hydrochloride (Renagel), a noncalcemic phosphate binder," *Nephron*, vol. 89, no. 3, pp. 321–328, 2001.
- [23] N. Nagano, S. Miyata, S. Obana et al., "Sevelamer hydrochloride, a calcium-free phosphate binder, inhibits parathyroid cell proliferation in partially nephrectomized rats," *Nephrology Dialysis Transplantation*, vol. 18, supplement 3, pp. iii81–iii85, 2003.
- [24] N. Nagano, S. Miyata, S. Obana et al., "Sevelamer hydrochloride, a phosphate binder, protects against deterioration of renal function in rats with progressive chronic renal insufficiency," *Nephrology Dialysis Transplantation*, vol. 18, no. 10, pp. 2014–2023, 2003.
- [25] N. Nagano, S. Miyata, S. Obana et al., "Sevelamer hydrochloride (Renagel), a non-calcemic phosphate binder, arrests parathyroid gland hyperplasia in rats with progressive chronic renal insufficiency," *Nephrology Dialysis Transplantation*, vol. 16, no. 9, pp. 1870–1878, 2001.
- [26] I. G. Nikolov, N. Joki, T. Nguyen-Khoa et al., "Lanthanum carbonate, like sevelamer-HCl, retards the progression of vascular calcification and atherosclerosis in uremic apolipoprotein E-deficient mice," *Nephrology Dialysis Transplantation*, vol. 27, no. 2, pp. 505–513, 2012.
- [27] O. Phan, O. Ivanovski, T. Nguyen-Khoa et al., "Sevelamer prevents uremia-enhanced atherosclerosis progression in apolipoprotein E-deficient mice," *Circulation*, vol. 112, no. 18, pp. 2875–2882, 2005.
- [28] D. P. Rosenbaum, S. R. Holmes-Farley, W. H. Mandeville, M. Pitruzzello, and D. I. Goldberg, "Effect of RenaGel(TM), a non-absorbable, cross-linked, polymeric phosphate binder, on urinary phosphorus excretion in rats," *Nephrology Dialysis Transplantation*, vol. 12, no. 5, pp. 961–964, 1997.
- [29] K. Terai, H. Nara, K. Takakura et al., "Vascular calcification and secondary hyperparathyroidism of severe chronic kidney disease and its relation to serum phosphate and calcium levels," *British Journal of Pharmacology*, vol. 156, no. 8, pp. 1267–1278, 2009.
- [30] "Renvela Prescribing Information," http://www.renvela.com/docs/pdf/RV382_Renvela.PI.08.2011.pdf
- [31] W. Braunlin, E. Zhorov, A. Guo et al., "Bile acid binding to sevelamer HCl," *Kidney International*, vol. 62, no. 2, pp. 611–619, 2002.
- [32] D. Pierce, S. Hossack, L. Poole et al., "The effect of sevelamer carbonate and lanthanum carbonate on the pharmacokinetics of oral calcitriol," *Nephrology Dialysis Transplantation*, vol. 26, no. 5, pp. 1615–1621, 2011.
- [33] M. Cozzolino, A. S. Dusso, H. Liapis et al., "The effects of sevelamer hydrochloride and calcium carbonate on kidney calcification in uremic rats," *Journal of the American Society of Nephrology*, vol. 13, no. 9, pp. 2299–2308, 2002.
- [34] M. Cozzolino, M. E. Staniforth, H. Liapis et al., "Sevelamer hydrochloride attenuates kidney and cardiovascular calcifications in long-term experimental uremia," *Kidney International*, vol. 64, no. 5, pp. 1653–1661, 2003.
- [35] H. Saito, A. Maeda, S. Ohtomo et al., "Circulating FGF-23 is regulated by 1 α ,25-dihydroxyvitamin D₃ and phosphorus *in vivo*," *The Journal of Biological Chemistry*, vol. 280, no. 4, pp. 2543–2549, 2005.
- [36] J. Magga, J. Kalliovalkama, H. Romppanen et al., "Differential regulation of cardiac adrenomedullin and natriuretic peptide gene expression by AT1 receptor antagonism and ACE inhibition in normotensive and hypertensive rats," *Journal of Hypertension*, vol. 17, no. 11, pp. 1543–1552, 1999.
- [37] I. Lopez, E. Aguilera-Tejero, F. J. Mendoza et al., "Calcimimetic R-568 decreases extraosseous calcifications in uremic rats treated with calcitriol," *Journal of the American Society of Nephrology*, vol. 17, no. 3, pp. 795–804, 2006.
- [38] I. de Brito-Ashurst, M. Varagunam, M. J. Raftery, and M. M. Yaqoob, "Bicarbonate supplementation slows progression of CKD and improves nutritional status," *Journal of the American Society of Nephrology*, vol. 20, no. 9, pp. 2075–2084, 2009.
- [39] W. G. Goodman and L. D. Quarles, "Development and progression of secondary hyperparathyroidism in chronic kidney disease: lessons from molecular genetics," *Kidney International*, vol. 74, no. 3, pp. 276–288, 2008.
- [40] R. E. laClair, R. N. Hellman, S. L. Karp et al., "Prevalence of calcidiol deficiency in CKD: a cross-sectional study across latitudes in the United States," *The American Journal of Kidney Diseases*, vol. 45, no. 6, pp. 1026–1033, 2005.
- [41] S. U. Nigwekar, I. Bhan, and R. Thadhani, "Ergocalciferol and cholecalciferol in CKD," *The American Journal of Kidney Diseases*, vol. 60, no. 1, pp. 139–156, 2012.
- [42] H. Taskapan, M. Wei, and D. G. Oreopoulos, "25(OH) vitamin D3 in patients with chronic kidney disease and those on dialysis: rediscovering its importance," *International Urology and Nephrology*, vol. 38, no. 2, pp. 323–329, 2006.
- [43] G. M. London, "Left ventricular hypertrophy: why does it happen?" *Nephrology Dialysis Transplantation*, vol. 18, no. 8, pp. v2–v4, 2003.
- [44] S. G. Achinger and J. C. Ayus, "The role of vitamin D in left ventricular hypertrophy and cardiac function," *Kidney International, Supplement*, vol. 67, no. 95, pp. S37–S42, 2005.
- [45] C. Faul, A. P. Amaral, B. Oskouei et al., "FGF23 induces left ventricular hypertrophy," *The Journal of Clinical Investigation*, vol. 121, no. 11, pp. 4393–4408, 2011.

- [46] K. A. Griffin, M. M. Picken, M. Churchill, P. Churchill, and A. K. Bidani, "Functional and structural correlates of glomerulosclerosis after renal mass reduction in the rat," *Journal of the American Society of Nephrology*, vol. 11, no. 3, pp. 497–506, 2000.
- [47] H. N. Ibrahim and T. H. Hostetter, "The renin-aldosterone axis in two models of reduced renal mass in the rat," *Journal of the American Society of Nephrology*, vol. 9, no. 1, pp. 72–76, 1998.
- [48] A. Eräranta, V. Kurra, A. M. Tahvanainen et al., "Oxonic acid-induced hyperuricemia elevates plasma aldosterone in experimental renal insufficiency," *Journal of Hypertension*, vol. 26, no. 8, pp. 1661–1668, 2008.
- [49] F. E. Karet, "Mechanisms in hyperkalemic renal tubular acidosis," *Journal of the American Society of Nephrology*, vol. 20, no. 2, pp. 251–254, 2009.